NEW YORK (GenomeWeb News) — Enigma Diagnostics has licensed two patents related to PCR technology from Roche Molecular Systems that will allow it to commercialize human and veterinary diagnostic tests worldwide, the company said today.
Porton Down, UK-based Enigma said that it has signed a term sheet for two patent licenses for the HybProbe real-time PCR chemistry and to commercialize HybProbe molecular diagnostics for human and animal testing. The company said these technologies complement its existing license for real-time PCR thermal cyclers from Celera Diagnostics.
Enigma is developing a series of multiplexed point-of-care assays for infectious diseases including chlamydia, influenza, and MRSA.
Financial terms of the agreement were not released.